Back to top
more

Hologic (HOLX)

(Delayed Data from NSDQ)

$67.81 USD

67.81
4,294,477

-0.25 (-0.37%)

Updated Aug 15, 2025 04:00 PM ET

After-Market: $67.84 +0.03 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (152 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Boston Scientific's Voraxaze's MAA Accepted by EMA for Review

by Zacks Equity Research

Boston Scientific's (BSX) business arm's MMA for Voraxaze (glucarpidase) accepted by EMA for review.

Zacks Equity Research

Here's Why You Should Hold on to ResMed (RMD) Stock for Now

by Zacks Equity Research

Investors continue to be upbeat about ResMed (RMD) owing to its potential in digital health and consistent high demand for its critical care products.

Zacks Equity Research

Pacific Biosciences (PACB) Catches Eye: Stock Jumps 6.6%

by Zacks Equity Research

Pacific Biosciences (PACB) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Zacks Equity Research

Amedisys Banks on Coronavirus-Driven Growth Amid Cost Woes

by Zacks Equity Research

Amedisys (AMED) has been benefiting from the recent acquisitions of hospice care providers.

Zacks Equity Research

EPA Validates NEOGEN's Disinfectant for Use Against COVID-19

by Zacks Equity Research

NEOGEN's (NEOG) BioSentry 904 Disinfectant approved by the EPA for use against the COVID-19-causing SARS-CoV-2 virus.

Zacks Equity Research

Omnicell, Pharmaceutical Strategies Enter Acquisition Deal

by Zacks Equity Research

Omnicell (OMCL) expands pharmacy supply chain capabilities for better management of 340B programs through the buyout of PSG's 340B Link business.

Sejuti Banerjea headshot

Long-Term Growth Rates Rising On These 5 Buy-Ranked Stocks

by Sejuti Banerjea

The long-term growth rate is a useful tool for value investors.

Zacks Equity Research

Cardiovascular Systems (CSII) Q4 Loss Narrower Than Expected (Revised)

by Zacks Equity Research

Cardiovascular Systems (CSII) registers significant decline in STEMI activations in Q4 earnings as patients avoid hospitals.

Zacks Equity Research

National Vision (EYE) Stock on the Rise Since Q2 Earnings Beat

by Zacks Equity Research

Investors seem to be impressed with National Vision's (EYE) better-than-expected second-quarter 2020 results despite the coronavirus-led economic crisis.

Zacks Equity Research

Syneos Health (SYNH) Q2 Earnings Top Estimates, Margins Down

by Zacks Equity Research

Syneos Health (SYNH) wins 35 COVID-19 related projects through the second quarter.

Zacks Equity Research

Integra (IART) Q2 Earnings Surpass Estimates, Margins Fall

by Zacks Equity Research

Integra's (IART) second-quarter 2020 results reflect disappointing segmental performance due to coronavirus-led business disruptions.

Zacks Equity Research

Insulet (PODD) Q2 Earnings Beat Estimates, 2020 View Up

by Zacks Equity Research

Insulet's (PODD) total Omnipod product line comes up with record revenue growth.

Zacks Equity Research

Globus Medical (GMED) Beats Q2 Earnings & Revenue Estimates

by Zacks Equity Research

Globus Medical (GMED) witnesses dismal segmental and international performance in the second quarter owing to pandemic-led adversities.

Zacks Equity Research

Illumina (ILMN) Q2 Earnings Miss Estimates, Margins Decline

by Zacks Equity Research

Illumina (ILMN) exhibits dismal performance in the second quarter of 2020 due to pandemic-led business disruptions.

Zacks Equity Research

Cardiovascular Systems (CSII) Misses Q4 Earnings Estimates

by Zacks Equity Research

Cardiovascular Systems (CSII) registers significant decline in STEMI activations in Q2 earnings as patients avoid hospitals.

Zacks Equity Research

NuVasive's (NUVA) Q2 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

NuVasive's (NUVA) operating segments experienced slowdown in second-quarter volumes due to the coronavirus pandemic.

Zacks Equity Research

ResMed (RMD) Q4 Earnings & Revenues Top Estimates, Margins Up

by Zacks Equity Research

ResMed's (RMD) top line reflects strong segmental and geographic performance boosted by pandemic-led demand growth for ventilators.

Zacks Equity Research

Why Hologic (HOLX) Could Be Positioned for a Surge

by Zacks Equity Research

Hologic (HOLX) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

Zacks Equity Research

CVS Health (CVS) Q2 Earnings Top Estimates, 2020 View Up

by Zacks Equity Research

CVS Health's (CVS) Health Care Benefits segment registers membership growth in Q2.

Zacks Equity Research

Intersect ENT (XENT) Q2 Loss Widens, Revenues Beat Estimates

by Zacks Equity Research

Although Intersect ENT's (XENT) Q2 sales are down year over year, it's stronger than expected, led by the return of sinus surgery procedures using PROPEL.

Zacks Equity Research

Haemonetics (HAE) Q1 Earnings Beat Estimates, Margins Down

by Zacks Equity Research

Haemonetics' (HAE) first-quarter fiscal 2021 results reflect impressive performance by Blood Center segment despite dismal overall performance during the coronavirus-led crisis.

Zacks Equity Research

QIAGEN (QGEN) Q2 Earnings In Line With Estimates, Margins Up

by Zacks Equity Research

QIAGEN (QGEN) registered robust revenue growth across majority of geographies and both operating segments in Q2 despite the coronavirus-led economic crisis.

Zacks Equity Research

Zimmer Biomet's (ZBH) Q2 Earnings Beat, Margins Contract

by Zacks Equity Research

Zimmer Biomet's (ZBH) second-quarter elective procedure volumes decline across all regions.

Zacks Equity Research

Bruker (BRKR) Q2 Earnings Surpass Estimates, Margins Fall

by Zacks Equity Research

Bruker's (BRKR) second-quarter 2020 results reflect dismal performance by all segments and geographies due to coronavirus-led business disruptions.

Zacks Equity Research

Henry Schein (HSIC) Q2 Earnings Top Estimates, Margins Dip

by Zacks Equity Research

Henry Schein (HSIC) sees dismal segmental performance in Q2 due to disruptions resulting from the coronavirus pandemic.